摘要
Adult T-cell lymphoblastic lymphoma(T-LBL)is characterized by its rarity and poor prognosis,however,it is currently being treated without any internationally recognized therapies[1].Acute lymphocytic leukemia(ALL)-like chemotherapy,such as the Berlin-Frankfurt-Muenster(BFM)regimen or the fractionated cyclophosphamide,vincristine,doxorubicin,and dexamethasone(hyperCVAD)regimen,is currently being widely used[2].